A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction - Summary - MDSpire
Advertisement
A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction
To identify the minimum intravenous dose of sodium ascorbate required for optimal therapeutic benefit in sepsis and evaluate its effects on organ dysfunction, addressing the limitations of current treatments.
Key Findings:
High-dose sodium ascorbate (3.75 g/kg) rapidly reversed pathophysiological effects of sepsis in preclinical studies, with significant improvements in urine output and reductions in vasopressor requirements specifically linked to this high-dose treatment.
Interpretation:
Achieving high plasma ascorbate concentrations is crucial for multi-organ protection in sepsis, with potential variations in effective dosing across different physiological systems, highlighting the need for tailored approaches in clinical settings.
Limitations:
Study conducted in a preclinical ovine model, which may not fully translate to human physiology, and ethical considerations in animal research may limit broader applicability.
Conclusion:
High-dose sodium ascorbate shows promise in reversing organ dysfunction in sepsis, warranting further investigation in multicenter clinical trials to validate these findings in human subjects.
by Connie Pei Chen Ow, Rachel M. Peiris, Anton Trask-Marino, Sally G. Hood, Ashenafi H. Betrie, Darius J. R. Lane, Rinaldo Bellomo, Mark P. Plummer, Clive N. May, Yugeesh R. Lankadeva
